Societe Generale analyst Justin Smith downgrades AbbVie (NYSE:ABBV) from Buy to Hold.
Alzheimer’s Approval, COVID-19 Vaccines Put Spotlight On Biotech Sector, But What’s Next?
For most of the past year, just a handful of companies carried the biotech sector, thanks to their quick responses to the COVID-19 pandemic.